Global Growth Hormone Deficiency Market Size, Share, and COVID-19 Impact Analysis, By Brand (Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and Others), By Applications (Pediatric Growth Hormone Deficiency, Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome, Adult Growth Hormone Deficiency, Prader-Willi Syndrome, and Others), By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Clinics, and E-Commerce Websites), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Growth Hormone Deficiency Market Insights Forecasts to 2035

• The Global Growth Hormone Deficiency Market Size Was Estimated at USD 5.67 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.1% from 2025 to 2035
• The Worldwide Growth Hormone Deficiency Market Size is Expected to Reach USD 9.80 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Spherical Insights and Consulting, the global growth hormone deficiency market size was worth around USD 5.67 billion in 2024 and is predicted to grow to around USD 9.80 billion by 2035 with a compound annual growth rate (CAGR) of 5.1% from 2025 to 2035. This growth in the market can be attributed to the increasing prevalence of hormonal disorders, better diagnostic capabilities, and advancements in recombinant and long-acting growth hormone therapies. Increased awareness, better access to healthcare facilities, and the expanding applications in both pediatric and adult populations are driving further growth in this market.

Market Overview

The global growth hormone deficiency (GHD) market refers to the industry concerned with the diagnosis, treatment, and management of growth hormone deficiency, a rare endocrine condition wherein the pituitary gland does not produce enough growth hormone to stimulate growth in children and normal metabolism in adults. Growth hormone therapy is mainly focused on recombinant human growth hormone (rhGH), used for stimulating growth and increasing muscle mass, as well as regulating metabolism. The rise in hormonal disorders due to an increase in the patient population and awareness among them and general physicians is expected to drive the market. Advances in biotechnology will also facilitate the creation of safer and more efficient recombinant and long-acting formulations. Innovation in drug delivery methodology, such as needle-free and once-weekly injectable systems, improves patient compliance and convenience, further propelling market growth.

These opportunities are further expanding with the currently ongoing clinical trials associated with novel applications of growth hormone therapy, including conditions related to ageing, Turner syndrome, and chronic kidney disease. Other supportive factors are the overall increase in healthcare expenditure arising from emerging economies and supportive government initiatives. Major companies in this market, such as Pfizer Inc., Novo Nordisk AS, Eli Lilly and Company, F. Hoffmann La Roche Ltd, Merck KGaA, and Novartis AG, keep investing in research and strategic collaborations as a competitive strategy to strengthen their portfolios. Considering increasing interest in personalized medicine and biotechnological innovation, the global growth hormone deficiency market is likely to continue to grow in the coming years. On March 10, 2025, Kerala's KARE (Kerala United Against Rare Diseases) project now provides free Growth Hormone (GH) therapy to children, with early detection of congenital disorders and professional care. At SAT Hospital, Thiruvananthapuram, 20 children, 14 with Turner syndrome and six suffering from GH deficiency, have started treatment following multidisciplinary evaluation. GH, produced by the pituitary, helps the growth of tissues, and 1-6 per 10,000 people are afflicted with a rare disease.

Report Coverage

This research report categorizes the growth hormone deficiency market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the growth hormone deficiency market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the growth hormone deficiency market. 

Driving Factors

The factors driving the growth of the growth hormone deficiency market include increased awareness and diagnosis of hormonal disorders, the growing prevalence of pituitary dysfunction, and the advancement of recombinant DNA technology to develop safer and more efficient growth hormone therapies. Expanding applications in adult GHD and anti-ageing treatments further support the demand for GH therapy. This, together with better healthcare infrastructure and reimbursement policies, has boosted the demand for growth disorders affecting a growing pediatric population. Besides this, ongoing R&D and the development of long-acting formulations of growth hormone increase patient compliance and, thereby, adoption. Strategic collaborations among biotech companies act to strengthen innovation and expand into geographical markets across the globe.

Restraining Factors

The high treatment costs, limited affordability in developing regions, and very stringent regulatory approval processes are acting as restraining factors on the growth of the growth hormone deficiency market. Potential side effects and safety concerns over the long-term use of hormones reduce adherence to these types of medications. Again, alternative therapy options and frequent injections impede this market from gaining widespread acceptance and growing at a higher rate.

Market Segmentation

The growth hormone deficiency market share is classified into brand, applications, and distribution channels.

• The norditropin segment dominated the market in 2024, approximately 30% and is projected to grow at a substantial CAGR during the forecast period.

Based on the brand, the growth hormone deficiency market is divided into norditropin, genotropin, humatrope, saizen, omnitrope and others. Among these, the norditropin segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. This segment dominated due to its growth is underpinned by strong brand recognition, an extensive global footprint, and a consistent demonstration of clinical efficacy. Also, a patient preference for reliable, easy-to-administer GH therapy, combined with ongoing awareness campaigns and expanding access in emerging markets, supports increased adoption. Innovations in delivery systems and long-acting formulations further contribute to its market leadership and sustained growth.

• The pediatric growth hormone deficiency segment accounted for the largest share in 2024, approximately 62% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the applications, the growth hormone deficiency market is divided into pediatric growth hormone deficiency, idiopathic short stature, small for gestational age, turner syndrome, adult growth hormone deficiency, prader-willi syndrome, and others. Among these, the pediatric growth hormone deficiency segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Awareness and early diagnosis of pediatric GHD, along with an increasing prevalence of growth disorder cases among children and improved access to effective therapies, have driven the growth of the pediatric growth hormone deficiency segment. This, along with improved long-acting GH formulation development, improved treatment adherence, and governmental support for orphan diseases related to children, has assured the continuous growth of this segment globally.

• The hospital pharmacies segment accounted for the highest market revenue in 2024, approximately 48% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the distribution channels, the growth hormone deficiency market is divided into hospital pharmacies, retail pharmacies, clinics, and e-commerce websites. Among these, the hospital pharmacies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The growth of the segment of hospital pharmacies is driven by the ability of hospitals to provide specialist diagnosis, continuous patient monitoring, and cold-chain storage for growth hormone therapies. Furthermore, this segment is being driven globally by growing hospital visits, preference for supervised treatments, and government initiatives toward hospital-based care for rare diseases.

Regional Segment Analysis of the Growth Hormone Deficiency Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the growth hormone deficiency market over the predicted timeframe.

North America is anticipated to hold the largest share of the growth hormone deficiency market over the predicted timeframe. North America will continue to account for the 42% share of the growth hormone deficiency market during the forecast period, driven by the United States due to its high healthcare expenditure, advanced infrastructure, and easy access to growth hormone therapies. Growth is supported by increasing awareness of GHD, early diagnosis in pediatric and adult patients, and strong insurance coverage for hormone treatments. Furthermore, continuous research, key market players, and supportive governmental initiatives on the management of rare diseases all combine to ensure continued strong market growth in this region.

Asia Pacific is expected to grow at a rapid CAGR in the growth hormone deficiency market during the forecast period. The Asia Pacific region is rapidly growing in the growth hormone deficiency market during the forecast period, with an approximate 23% market share, and will be driven mainly by countries such as China and India. Growth is driven by increasing awareness of pediatric and adult GHD, rising healthcare expenditure, expanding healthcare infrastructure, and improving access to advanced therapies. Government initiatives for the treatment of rare diseases, growing diagnostic capabilities, and a large patient population further fuel market expansion. In addition, several multinational pharmaceutical companies are extending their presence in the region, improving therapy availability and adoption.

Europe holds a significant share in the growth hormone deficiency (GHD) market, with Germany, the UK, and France as leading contributors. Market growth is driven by high awareness of GHD, well-established healthcare systems, and strong reimbursement policies for hormone therapies. Early diagnosis programs, advanced medical infrastructure, and ongoing research in growth disorders further support adoption. Additionally, government initiatives for rare diseases and the availability of advanced GH formulations contribute to steady market expansion across the region.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the growth hormone deficiency market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer Inc.
• Novo Nordisk A/S
• Ipsen S.A.
• Merck KGaA
• Eli Lilly and Company
• Ferring Pharmaceuticals
• Novartis AG
• AnkeBio Co Ltd
• F. Hoffmann La Roche Ltd
• EMD Serono Inc
• Ascendis Pharma A/S
• Teva Pharmaceutical Industries Ltd.
• Anhui Anke Biotechnology Group Co., Ltd
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In July 2025, Ascendis Pharma announced FDA approval of SKYTROFA (lonapegsomatropin tcgd) for adult growth hormone deficiency (GHD). Previously approved in 2021 for pediatric GHD, this once-weekly prodrug of somatropin provides sustained release of active human growth hormone, replacing deficient endogenous GH in adults.
• In May 2025, Merck launched a next-generation digital ecosystem for Growth Hormone Deficiency, highlighting its focus on innovative patient care. This initiative contrasts broader market trends, where investor sentiment remains mixed due to anticipated Federal Reserve interest rate decisions and ongoing trade discussions affecting the healthcare and pharmaceutical sectors.
• In September 2023, Ascendis Pharma launched SKYTROFA (lonapegsomatropin) in Germany. Approved in the EU, it provides once-weekly treatment for children and adolescents aged 3-18 years with growth failure caused by insufficient endogenous growth hormone secretion (GHD), offering a convenient and effective therapy for pediatric growth hormone deficiency.
• In June 2023, Pfizer and OPKO Health announced FDA approval of NGENLA (somatrogon ghla), a once-weekly human growth hormone analogue for pediatric patients aged three and older with growth failure due to insufficient endogenous GH. NGENLA is expected to be available for U.S. prescriptions starting August 2023.
• In January 2022, Pfizer and OPKO Health announced that the FDA issued a Complete Response Letter for the Biologics License Application of somatrogon, a once-weekly long-acting recombinant human growth hormone for pediatric GHD. Pfizer is reviewing the FDA’s feedback and collaborating to determine the next steps for approval.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the growth hormone deficiency market based on the below-mentioned segments:  

Global Growth Hormone Deficiency Market, By Brand

• Norditropin
• Genotropin
• Humatrope
• Saizen
• Omnitrope
• Others

Global Growth Hormone Deficiency Market, By Applications

• Pediatric Growth Hormone Deficiency
• Idiopathic Short Stature
• Small for Gestational Age
• Turner Syndrome
• Adult Growth Hormone Deficiency
• Prader-Willi Syndrome
• Others

Global Growth Hormone Deficiency Market, By Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• Clinics
• E-Commerce Websites

Global Growth Hormone Deficiency Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa